Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial (Q41444409)

30 September 2017

Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial (English)

1 reference

chronic renal insufficiency

30 September 2017

1 reference

Kenichi Tanaka

1

1 reference

30 September 2017

Masaaki Nakayama

2

1 reference

30 September 2017

Makoto Kanno

3

1 reference

30 September 2017

Hiroshi Kimura

4

1 reference

30 September 2017

Kimio Watanabe

5

1 reference

30 September 2017

Yoshihiro Tani

6

1 reference

30 September 2017

Yoshimitsu Hayashi

7

1 reference

30 September 2017

Koichi Asahi

8

1 reference

30 September 2017

Hiroyuki Terawaki

9

1 reference

30 September 2017

Tsuyoshi Watanabe

10

1 reference

30 September 2017

language of work or name

1 reference

13 February 2015

1 reference

Clinical and experimental nephrology

30 September 2017

1 reference

30 September 2017

19

1 reference

30 September 2017

1044-1053

1 reference

30 September 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1007/s10157-015-1095-1

30 September 2017

0 references

cites work

Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Relationship of uric acid with progression of kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Uric acid and incident kidney disease in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Uric acid and long-term outcomes in CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

J-shaped mortality relationship for uric acid in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Revised equations for estimated GFR from serum creatinine in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Association of uric acid with change in kidney function in healthy normotensive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Preservation of renal function during gout treatment with febuxostat: a quantitative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Hyperuricemia induces endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Circulating mononuclear cells nuclear factor-kappa B activity, plasma xanthine oxidase, and low grade inflammatory markers in adult patients with familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1095-1

Epidemiology of cardiovascular disease in chronic renal disease

21 January 2018

1 reference

12 December 2020

Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction

1 reference

12 December 2020

A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population.

1 reference

12 December 2020

Effect of allopurinol on blood pressure (author response to Allopurinol on hypertension: insufficient evidence to recommend).

1 reference

12 December 2020

Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort

1 reference

12 December 2020

Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population--the Ohasama study

1 reference

12 December 2020

Uric acid and cardiovascular risk

1 reference

12 December 2020

Can febuxostat reduce triglyceride and cholesterol serum levels in gouty patients?

1 reference

12 December 2020

Renal involvement follows cardiac enlargement in essential hypertension.

1 reference

12 December 2020

Xanthine oxidase and triglycerides in serum of patients with hyperlipoproteinemia, type IV

1 reference

12 December 2020

10.1007/S10157-015-1095-1

Identifiers

DOI

1 reference

30 September 2017

1 reference